GlobeNewsWire - WAVE Life Sciences (WVE) Wave Life Sciences Announces Suvodirsen Phase 1 Safety and Tolerability Data and Phase 2/3 Clinical Trial Design

Almost there...

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

First Name*

Last Name*

Country*

Email*

Password* ( 6 or more alphabetic and numerical characters )

Get financial insights straight to your inbox

YES

I have read and accept ResearchPool Terms & Conditions, and Privacy Policy, including our Cookie Use Policy

Already on ResearchPool? Login Now

WVE WAVE Life Sciences

Wave Life Sciences Announces Suvodirsen Phase 1 Safety and Tolerability Data and Phase 2/3 Clinical Trial Design

Data to be presented today at 2019 Muscular Dystrophy Association Clinical and Scientific Conference

Phase 2/3 clinical trial for suvodirsen in DMD expected to initiate in July 2019

Interim efficacy data from ongoing open-label extension study expected in H2 2019

Investor conference call scheduled for 7:30 a.m. ET today to discuss Phase 1 results and Phase 2/3 trial design

CAMBRIDGE, Mass., April 16, 2019 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for p

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

WVE WAVE Life Sciences

Wave Life Sciences Announces Suvodirsen Phase 1 Safety and Tolerability Data and Phase 2/3 Clinical Trial Design

Wave Life Sciences Announces Suvodirsen Phase 1 Safety and Tolerability Data and Phase 2/3 Clinical Trial Design